ALPMY
ASTELLAS PHARMA UNSP/ADR
stock OTC ADR

Hey everyone,
Back with the weekly catalyst briefing. For those who don't know me, I'm the dev behind [CatalystAlert.io](https://catalystalert.io), I build tools to track biotech catalysts. Each week I pull the data from our calendar and put together a summary of what's coming up. Not investment advice, just laying out the facts so you can do your own research.
The next 2-3 weeks are stacked. Here's the breakdown.
# This Week (Mar 22-28) - Several PDUFA dates + big Phase 3 readouts
**PDUFA / FDA Decision Dates:**
* **OTLK** (Outlook Therapeutics) — PDUFA date March 23. Small-cap ophthalmic company.
* **GSK** (GSK plc) — PDUFA date March 24. Details on the specific drug pending.
* **GMAB** (Genmab) — Tisotumab vedotin PDUFA around March 26 for solid tumors. **Already approved** per our data.
* **RYTM** (Rhythm Pharmaceuticals) — Setmelanotide PDUFA around March 27 for genetic obesity. Rhythm is focused on rare genetic diseases of obesity — meaningful unmet need.
* **IONS** (Ionis Pharmaceuticals) — Inotersen PDUFA around March 27 for FAP (Familial Amyloid Polyneuropathy). **Already approved** per our data. $5.7B company.
* **JAZZ** (Jazz Pharmaceuticals) — PDUFA date March 28. $8B+ company, details pending.
* **LNTH** (Lantheus Holdings) — PDUFA date March 29. Lantheus is a \~$4B diagnostic imaging company.
**Phase 3 Readouts:**
* **PFE** (Pfizer) — Ritlecitinib Phase 3 in nonsegmental vitiligo, March 22. Already approved for alopecia areata — this would be a label expansion. **Positive results reported.** $142.7B company.
* **OTSKF** (Otsuka) — Centanafadine Phase 3 in ADHD around March 25. Novel non-stimulant mechanism in a massive market. $34B company.
* **MLTX** (MoonLake Immunotherapeutics) — Sonelokimab Phase 3 in hidradenitis suppurativa around March 27. \~$1.1B company, lead program, novel nanobody format targeting an underserved condition. One to watch.
# Late March (Mar 29-31) — Roche-heavy + several notable readouts
**Phase 3 Readouts:**
* **AZN** (AstraZeneca) — Two Phase 3 readouts around March 30: Cisplatin combo in muscle-invasive bladder cancer, and Carboplatin in locally advanced/metastatic cancers. $291B company.
* **NVS** (Novartis) — Remibrutinib Phase 3 in relapsing multiple sclerosis around March 30. BTK inhibitors in MS are getting major attention across the industry. $274B company. Also TQJ230 Phase 3 data for elevated Lp(a) — **positive results reported**.
* **RHHBY** (Roche) — Three Phase 3 readouts expected end of month: Lenvatinib in HCC (**positive**), Atezolizumab in HCC (**positive**), and Giredestrant in endometrial cancer. $344B company. Endocrine therapy data in early breast cancer also expected.
* **URGN** (UroGen Pharma) — UGN-104 Phase 3 in upper tract urothelial carcinoma around March 31. $675M company with a differentiated delivery approach.
* **ALPMY** (Astellas Pharma) — Fezolinetant Phase 3 in hot flashes, March 31. $25.6B company.
# Early April (Apr 1-10) — PDUFA wave + major Phase 3 data
**PDUFA / FDA Decision Dates:**
* **LLY** (Eli Lilly) — Orforglipron PDUFA around April 1 for **obesity (oral GLP-1)**. This is potentially one of the biggest FDA decisions of the year — oral GLP-1 in a market currently dominated by injectable Wegovy/Mounjaro. $769B company. All eyes on this one.
* **BMRN** (BioMarin) — PDUFA date April 1. $11B rare disease company.
* **RCKT** (Rocket Pharmaceuticals) — RP-L201 PDUFA around April 2 for Leukocyte Adhesion Deficiency Type I. Gene therapy approach for a severe rare disease. Priority review.
* **DNLI** (Denali Therapeutics) — Tividenofusp alfa PDUFA around April 5 for Hunter Syndrome (MPS II). Breakthrough potential for this lysosomal storage disorder.
* **FBIOP** (Fortress Biotech) — PDUFA date April 6.
* **ROIV** (Roivant Sciences) — PDUFA date April 9.
* **CORT** (Corcept Therapeutics) — PDUFA date April 9. Relacorilant for Cushing's syndrome.
* **ASND** (Ascendis Pharma) — TransCon CNP PDUFA around April 10 for achondroplasia.
**Phase 3 Readouts:**
* **VRDN** (Viridian Therapeutics) — VRDN-003 Phase 3 in Thyroid Eye Disease around April 1. $732M company competing in the TED space against Horizon's Tepezza.
* **INCY** (Incyte) — Tafasitamab + Lenalidomide Phase 3 in large B-cell lymphoma around April 1. $9.9B company.
* **SNY** (Sanofi) — Isatuximab (Sarclisa) Phase 3 in multiple myeloma around April 5. $115B company. Also Bortezomib combo data.
* **NVS** (Novartis) — LOU064 Phase 3 in chronic spontaneous urticaria around April 2. **Positive results reported.** $274B company.
# PDUFA dates — Looking ahead (April-May)
The queue keeps building after early April:
|Expected|Ticker|Company|Drug|Indication|
|:-|:-|:-|:-|:-|
|Apr 15|PHAR|Pharming|Leniolisib|PIDs (PI3K) — **Already approved**|
|Apr 16|SNY|Sanofi|Sutimlimab|Cold Agglutinin Disease — **Approved**|
|Apr 23|MRK|Merck|—|—|
|Apr 28|INSM|Insmed|Arikayce|Cystic Fibrosis|
|Apr 30|CYTK|Cytokinetics|Omecamtiv Mecarbil|Heart Failure (HFrEF)|
|May 7|ATHA|Athira Pharma|ATH-1017|Alzheimer's Disease|
|May 10|ARVN|Arvinas|ARV-471|Breast Cancer|
# Notable themes to watch
**LLY Orforglipron (Apr 1)** — Probably the highest-profile PDUFA of the month. First oral GLP-1 for obesity. The GLP-1 market is projected at $100B+ by 2030. An oral formulation would be a game-changer for patient access.
**The PDUFA wave is real** — We count 15+ FDA decision dates between now and April 15. That's significantly above average.
**Roche's late-March data dump** — Three Phase 3 readouts in one week for a $344B company. HCC data already positive, endometrial cancer and early breast cancer data still pending.
**Novartis Remibrutinib in MS** — BTK inhibitors are emerging as a new class for MS treatment. This readout, alongside Roche and Sanofi's similar programs, could shape the future of MS therapy.
**Denali Tividenofusp in Hunter Syndrome (Apr 5)** — Potential first treatment for MPS II that crosses the blood-brain barrier. Meaningful for the rare disease community.
# New: Free educational content on CatalystAlert
We recently launched [**catalystalert.io/learn**](https://catalystalert.io/learn) — a free educational hub for biotech investors. Covers the fundamentals that every biotech investor should know:
* **PDUFA Dates Explained** — What FDA action dates mean, how user fee agreements work, and why dates shift (8 min read)
* **Advisory Committee Meetings** — How AdCom votes work, voting procedures, and their real impact on approval odds (10 min)
* **NDA vs BLA Applications** — The difference between drug and biologics applications (6 min)
* **Clinical Trial Phases** — Deep dive into Phase 1/2/3 design, endpoints, and historical success rates (12 min)
* **FDA Special Designations** — Orphan Drug, Breakthrough Therapy, Fast Track, Priority Review explained (9 min)
* **Biotech Catalyst Trading** — How to identify, track, and position around catalysts (15 min)
All free, no signup required. Built for retail investors who want to understand the space better.
**Disclaimer:** CatalystAlert.io is currently in **beta**. The data presented in this post is provided for informational purposes only and does not constitute investment advice. We are not a source of truth — dates, drug names, trial phases, and any other data points may contain errors, be outdated, or be inaccurate. Catalyst dates can shift without notice, trials get delayed or cancelled, and outcomes are inherently uncertain. All information should be independently verified against official sources (SEC filings, FDA.gov, ClinicalTrials.gov, company press releases) before making any decisions. We assume no responsibility for any errors or actions taken based on this information. Use at your own risk.
We're actively building and improving. If you spot wrong data, have feature requests, or want to give feedback — we genuinely want to hear it. Drop a comment or hit me up. Every piece of critical feedback makes the product better.
All data pulled from [CatalystAlert.io](https://catalystalert.io) — built to track exactly this kind of stuff.

Hey everyone,
Back with the weekly catalyst briefing. For those who don't know me, I'm the dev behind [CatalystAlert.io](https://catalystalert.io), I build tools to track biotech catalysts. Each week I pull the data from our calendar and put together a summary of what's coming up. Not investment advice, just laying out the facts so you can do your own research.
The next 2-3 weeks are stacked. Here's the breakdown.
# This Week (Mar 22-28) - Several PDUFA dates + big Phase 3 readouts
**PDUFA / FDA Decision Dates:**
* **OTLK** (Outlook Therapeutics) — PDUFA date March 23. Small-cap ophthalmic company.
* **GSK** (GSK plc) — PDUFA date March 24. Details on the specific drug pending.
* **GMAB** (Genmab) — Tisotumab vedotin PDUFA around March 26 for solid tumors. **Already approved** per our data.
* **RYTM** (Rhythm Pharmaceuticals) — Setmelanotide PDUFA around March 27 for genetic obesity. Rhythm is focused on rare genetic diseases of obesity — meaningful unmet need.
* **IONS** (Ionis Pharmaceuticals) — Inotersen PDUFA around March 27 for FAP (Familial Amyloid Polyneuropathy). **Already approved** per our data. $5.7B company.
* **JAZZ** (Jazz Pharmaceuticals) — PDUFA date March 28. $8B+ company, details pending.
* **LNTH** (Lantheus Holdings) — PDUFA date March 29. Lantheus is a \~$4B diagnostic imaging company.
**Phase 3 Readouts:**
* **PFE** (Pfizer) — Ritlecitinib Phase 3 in nonsegmental vitiligo, March 22. Already approved for alopecia areata — this would be a label expansion. **Positive results reported.** $142.7B company.
* **OTSKF** (Otsuka) — Centanafadine Phase 3 in ADHD around March 25. Novel non-stimulant mechanism in a massive market. $34B company.
* **MLTX** (MoonLake Immunotherapeutics) — Sonelokimab Phase 3 in hidradenitis suppurativa around March 27. \~$1.1B company, lead program, novel nanobody format targeting an underserved condition. One to watch.
# Late March (Mar 29-31) — Roche-heavy + several notable readouts
**Phase 3 Readouts:**
* **AZN** (AstraZeneca) — Two Phase 3 readouts around March 30: Cisplatin combo in muscle-invasive bladder cancer, and Carboplatin in locally advanced/metastatic cancers. $291B company.
* **NVS** (Novartis) — Remibrutinib Phase 3 in relapsing multiple sclerosis around March 30. BTK inhibitors in MS are getting major attention across the industry. $274B company. Also TQJ230 Phase 3 data for elevated Lp(a) — **positive results reported**.
* **RHHBY** (Roche) — Three Phase 3 readouts expected end of month: Lenvatinib in HCC (**positive**), Atezolizumab in HCC (**positive**), and Giredestrant in endometrial cancer. $344B company. Endocrine therapy data in early breast cancer also expected.
* **URGN** (UroGen Pharma) — UGN-104 Phase 3 in upper tract urothelial carcinoma around March 31. $675M company with a differentiated delivery approach.
* **ALPMY** (Astellas Pharma) — Fezolinetant Phase 3 in hot flashes, March 31. $25.6B company.
# Early April (Apr 1-10) — PDUFA wave + major Phase 3 data
**PDUFA / FDA Decision Dates:**
* **LLY** (Eli Lilly) — Orforglipron PDUFA around April 1 for **obesity (oral GLP-1)**. This is potentially one of the biggest FDA decisions of the year — oral GLP-1 in a market currently dominated by injectable Wegovy/Mounjaro. $769B company. All eyes on this one.
* **BMRN** (BioMarin) — PDUFA date April 1. $11B rare disease company.
* **RCKT** (Rocket Pharmaceuticals) — RP-L201 PDUFA around April 2 for Leukocyte Adhesion Deficiency Type I. Gene therapy approach for a severe rare disease. Priority review.
* **DNLI** (Denali Therapeutics) — Tividenofusp alfa PDUFA around April 5 for Hunter Syndrome (MPS II). Breakthrough potential for this lysosomal storage disorder.
* **FBIOP** (Fortress Biotech) — PDUFA date April 6.
* **ROIV** (Roivant Sciences) — PDUFA date April 9.
* **CORT** (Corcept Therapeutics) — PDUFA date April 9. Relacorilant for Cushing's syndrome.
* **ASND** (Ascendis Pharma) — TransCon CNP PDUFA around April 10 for achondroplasia.
**Phase 3 Readouts:**
* **VRDN** (Viridian Therapeutics) — VRDN-003 Phase 3 in Thyroid Eye Disease around April 1. $732M company competing in the TED space against Horizon's Tepezza.
* **INCY** (Incyte) — Tafasitamab + Lenalidomide Phase 3 in large B-cell lymphoma around April 1. $9.9B company.
* **SNY** (Sanofi) — Isatuximab (Sarclisa) Phase 3 in multiple myeloma around April 5. $115B company. Also Bortezomib combo data.
* **NVS** (Novartis) — LOU064 Phase 3 in chronic spontaneous urticaria around April 2. **Positive results reported.** $274B company.
# PDUFA dates — Looking ahead (April-May)
The queue keeps building after early April:
|Expected|Ticker|Company|Drug|Indication|
|:-|:-|:-|:-|:-|
|Apr 15|PHAR|Pharming|Leniolisib|PIDs (PI3K) — **Already approved**|
|Apr 16|SNY|Sanofi|Sutimlimab|Cold Agglutinin Disease — **Approved**|
|Apr 23|MRK|Merck|—|—|
|Apr 28|INSM|Insmed|Arikayce|Cystic Fibrosis|
|Apr 30|CYTK|Cytokinetics|Omecamtiv Mecarbil|Heart Failure (HFrEF)|
|May 7|ATHA|Athira Pharma|ATH-1017|Alzheimer's Disease|
|May 10|ARVN|Arvinas|ARV-471|Breast Cancer|
# Notable themes to watch
**LLY Orforglipron (Apr 1)** — Probably the highest-profile PDUFA of the month. First oral GLP-1 for obesity. The GLP-1 market is projected at $100B+ by 2030. An oral formulation would be a game-changer for patient access.
**The PDUFA wave is real** — We count 15+ FDA decision dates between now and April 15. That's significantly above average.
**Roche's late-March data dump** — Three Phase 3 readouts in one week for a $344B company. HCC data already positive, endometrial cancer and early breast cancer data still pending.
**Novartis Remibrutinib in MS** — BTK inhibitors are emerging as a new class for MS treatment. This readout, alongside Roche and Sanofi's similar programs, could shape the future of MS therapy.
**Denali Tividenofusp in Hunter Syndrome (Apr 5)** — Potential first treatment for MPS II that crosses the blood-brain barrier. Meaningful for the rare disease community.
# New: Free educational content on CatalystAlert
We recently launched [**catalystalert.io/learn**](https://catalystalert.io/learn) — a free educational hub for biotech investors. Covers the fundamentals that every biotech investor should know:
* **PDUFA Dates Explained** — What FDA action dates mean, how user fee agreements work, and why dates shift (8 min read)
* **Advisory Committee Meetings** — How AdCom votes work, voting procedures, and their real impact on approval odds (10 min)
* **NDA vs BLA Applications** — The difference between drug and biologics applications (6 min)
* **Clinical Trial Phases** — Deep dive into Phase 1/2/3 design, endpoints, and historical success rates (12 min)
* **FDA Special Designations** — Orphan Drug, Breakthrough Therapy, Fast Track, Priority Review explained (9 min)
* **Biotech Catalyst Trading** — How to identify, track, and position around catalysts (15 min)
All free, no signup required. Built for retail investors who want to understand the space better.
**Disclaimer:** CatalystAlert.io is currently in **beta**. The data presented in this post is provided for informational purposes only and does not constitute investment advice. We are not a source of truth — dates, drug names, trial phases, and any other data points may contain errors, be outdated, or be inaccurate. Catalyst dates can shift without notice, trials get delayed or cancelled, and outcomes are inherently uncertain. All information should be independently verified against official sources (SEC filings, FDA.gov, ClinicalTrials.gov, company press releases) before making any decisions. We assume no responsibility for any errors or actions taken based on this information. Use at your own risk.
We're actively building and improving. If you spot wrong data, have feature requests, or want to give feedback — we genuinely want to hear it. Drop a comment or hit me up. Every piece of critical feedback makes the product better.
All data pulled from [CatalystAlert.io](https://catalystalert.io) — built to track exactly this kind of stuff.